FDA expands Roche HER2 companion diagnostics for ZIIHERA in gastroesophageal cancer
Roche has secured expanded FDA approval for two HER2 companion diagnostics used to identify gastroesophageal adenocarcinoma patients who may be eligible for Jazz Pharmaceuticals’ ZIIHERA.